Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study
Authors:
- Othman AlharbiOAOthman Alharbi
- Abdulrahman M. AljebreenAAAbdulrahman M. Aljebreen
- Nahla A. AzzamNANahla A. Azzam
- Majid A. AlmadiMAMajid A. Almadi
- Maria SaeedMSMaria Saeed
- Baraa HajkhderMullaissaBHBaraa HajkhderMullaissa
- Hassan AsiriHAHassan Asiri
- Abdullah AlmutairiAAAbdullah Almutairi
- Yazed AlRuthiaYAYazed AlRuthia
Open Access
- 18 July 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (14) , 4157
Abstract
Background: The advent of monoclonal antibodies (mAbs) has revolutionized the management of many immune-mediated diseases such as inflammatory bowel disease (IBD). Infliximab and adalimumab were the first mAbs approved for the management of IBD, and are still commonly prescribed for the treatment of both Crohn’s disease (CD) and ulcerative colitis (UC). Although mAbs have demonstrated high effectiveness rates in the management of IBD, some patients fail to respond adequately to mAbs, resulting in disease progression and the flare-up of symptoms. Objective: The objective was to explore the predictors of treatment failure among IBD patients on infliximab (INF) and adalimumab (ADA)—as demonstrated via colonoscopy with a simple endoscopic score (SES–CD) of ≥1 for CD and a Mayo score of ≥2 for UC—and compare the rates of treatment failure among patients on those two mAbs. Methods: This was a prospective cohort study among IBD patients aged 18 years and above who had not had any exposure to mAbs before. Those patients were followed after the initiation of biologic treatment with either INF or ADA until they were switched to another treatment due to failure of these mAbs in preventing the disease progression. Univariate and multiple logistic regressions were conducted to examine the predictors and rates of treatment failure. Results: A total of 146 IBD patients (118 patients on INF and 28 on ADA) met the inclusion criteria and were included in the analysis. The mean age of the patients was 31 years, and most of them were males (59%) with CD (75%). About 27% and 26% of the patients had penetrating and non-stricturing–non-penetrating CD behavior, respectively. Patients with UC had significantly higher odds of treatment failure compared to their counterparts with CD (OR = 2.58, 95% CI [1.06–6.26], p = 0.035). Those with left-sided disease had significantly higher odds of treatment failure (OR = 4.28, 95% CI [1.42–12.81], p = 0.0094). Patients on ADA had higher odds of treatment failure in comparison to those on INF (OR = 26.91, 95% CI [7.75–93.39], p = 0.0001). Conclusion: Infliximab was shown to be more effective in the management of IBD, with lower incidence rates of treatment failure in comparison to adalimumab.Keywords
Funding Information
- Researchers Support-ing Project, King Saud University, Riyadh, Saudi Arabia (RSP-2021/16)
This publication has 42 references indexed in Scilit:
- Implementation of the simple endoscopic activity score in crohn's diseaseSaudi Journal of Gastroenterology, 2016
- Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical managementAlimentary Pharmacology & Therapeutics, 2015
- Efficacy and safety of anti‐TNF therapy in elderly patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2015
- Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failedAlimentary Pharmacology & Therapeutics, 2015
- Colonoscopic evaluation in ulcerative colitisGastroenterology Report, 2014
- Clinical epidemiology of ulcerative colitis in Arabs based on the Montréal classificationWorld Journal of Gastroenterology, 2014
- Clinical epidemiology and phenotypic characteristics of Crohn′s disease in the central region of Saudi ArabiaSaudi Journal of Gastroenterology, 2014
- Optimizing anti-TNF treatments in inflammatory bowel diseaseAutoimmunity Reviews, 2014
- Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2013
- High incidence of inflammatory bowel disease in Australia: A prospective population-based Australian incidence studyInflammatory Bowel Diseases, 2010